Graham MA - Search Results

1

Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation.

Foster BJ, Newell DR, Graham MA, Gumbrell LA, Jenns KE, Kaye SB, Calvert AH. Foster BJ, et al. Among authors: graham ma. Eur J Cancer. 1992;28(2-3):463-9. doi: 10.1016/s0959-8049(05)80077-2. Eur J Cancer. 1992. PMID: 1591064 Clinical Trial.

2

The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.

Graham MA, Newell DR, Foster BJ, Calvert AH. Graham MA, et al. Cancer Chemother Pharmacol. 1989;23(1):8-14. doi: 10.1007/BF00258450. Cancer Chemother Pharmacol. 1989. PMID: 2909292

3

Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.

Graham MA, Newell DR, Foster BJ, Gumbrell LA, Jenns KE, Calvert AH. Graham MA, et al. Cancer Res. 1992 Feb 1;52(3):603-9. Cancer Res. 1992. PMID: 1732048 Clinical Trial.

4

Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.

Graham MA, Senan S, Robin H Jr, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P. Graham MA, et al. Cancer Chemother Pharmacol. 1997;40(1):1-10. doi: 10.1007/s002800050617. Cancer Chemother Pharmacol. 1997. PMID: 9137522 Clinical Trial.

5

Phase I pharmacokinetic study of the novel antitumor agent SR233377.

LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK, McCormick JI, Ruble PE, Graham MA, Purvis J, Rake J, Drozd M, Lockwood GF, Corbett TH. LoRusso PM, et al. Among authors: graham ma. Clin Cancer Res. 2000 Aug;6(8):3088-94. Clin Cancer Res. 2000. PMID: 10955788 Clinical Trial.

6

Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.

Graham MA, Bissett D, Setanoians A, Hamilton T, Kerr DJ, Henrar R, Kaye SB. Graham MA, et al. J Natl Cancer Inst. 1992 Apr 1;84(7):494-500. doi: 10.1093/jnci/84.7.494. J Natl Cancer Inst. 1992. PMID: 1545439 Clinical Trial.

7

Phase I and pharmacokinetic study of rhizoxin.

Bissett D, Graham MA, Setanoians A, Chadwick GA, Wilson P, Koier I, Henrar R, Schwartsmann G, Cassidy J, Kaye SB, et al. Bissett D, et al. Among authors: graham ma. Cancer Res. 1992 May 15;52(10):2894-8. Cancer Res. 1992. PMID: 1581905 Clinical Trial.

8

Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).

Judson IR, Calvert AH, Rutty CJ, Abel G, Gumbrell LA, Graham MA, Evans BD, Wilman DE, Ashley SE, Cairnduff F. Judson IR, et al. Among authors: graham ma. Cancer Res. 1989 Oct 1;49(19):5475-9. Cancer Res. 1989. PMID: 2670205 Clinical Trial.

9

Determination of the anthrapyrazole anticancer drug CI-941 in plasma and urine by solid-phase extraction and high-performance liquid chromatography.

Graham MA, Newell DR, Calvert AH. Graham MA, et al. J Chromatogr. 1989 Jun 30;491(1):253-61. doi: 10.1016/s0378-4347(00)82841-8. J Chromatogr. 1989. PMID: 2793977 No abstract available.

10

New approaches in preclinical and clinical pharmacokinetics.

Graham MA, Kaye SB. Graham MA, et al. Cancer Surv. 1993;17:27-49. Cancer Surv. 1993. PMID: 8137345 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters